论文部分内容阅读
目的：探讨卵巢肿瘤中癌基因Ｃ－ｅｒｂＢ２及抑癌基因ｐ１６的表达及其与临床病理特征及患者预后的关系。方法：用免疫组化ＡＢＣ法，分析４９份卵巢恶性肿瘤、１２份交界性肿瘤、１５份良性肿瘤石蜡包埋组织中Ｃ－ｅｒｂＢ２、ｐ１６的表达情况。结果：①在卵巢恶性肿瘤、交界性肿瘤、良性肿瘤之间Ｃ－ｅｒｂＢ２的表达差异有显著性（Ｐ＜０．０１）。Ｃ－ｅｒｂＢ２的表达率及表达强度与组织分化程度患者及生存期有显著相关性（Ｐ＜０．０５），Ｃ－ｅｒｂＢ２的过度表达见于恶性程度高、组织分化差、患者预后不良的肿瘤中。②在卵巢恶性肿瘤、交界性肿瘤、良性肿瘤之间ｐ１６的表达差异有显著性（Ｐ＜０．０１）。其表达强度与组织分化程度及临床分期有显著相关性，在恶性程度较高、组织分化差、较晚期的肿瘤中ｐ１６的表达较弱。结论：癌基因Ｃ－ｅｒｂＢ２及抑癌基因ｐ１６在卵巢癌组织中广泛存在，并与其临床病理指标之间有一定的相关性，提示这些基因在卵巢癌的发生、发展中起一定作用，并对患者预后的判断及治疗有一定的指导意义。对各基因之间复杂的相互作用、协同作用有待进一步研究。
Objective: To investigate the expression of oncogene C-erbB2 and tumor suppressor gene p16 in ovarian tumors and its relationship with clinicopathological features and prognosis. Methods: Immunohistochemical ABC method was used to analyze the expression of C-erbB2 and p16 in paraffin-embedded tissues of 49 ovarian malignancies, 12 borderline tumors and 15 benign tumors. Results ① The expression of C-erbB2 in ovarian cancer, borderline tumor and benign tumor was significantly different (P <0.01). The expression of C-erbB2 was correlated with the degree of tissue differentiation and the survival of patients (P <0.05). The overexpression of C-erbB2 was found in tumors with high malignant degree, poor tissue differentiation and poor prognosis . ② The expression of p16 in ovarian cancer, borderline tumor and benign tumor was significantly different (P <0.01). The expression intensity was significantly correlated with the degree of tissue differentiation and clinical stage. The expression of p16 was weak in tumors with higher malignant degree, poor tissue differentiation and more advanced stage. Conclusion: The oncogene C-erbB2 and the tumor suppressor gene p16 are widely found in ovarian cancer tissues and have some correlation with clinicopathological parameters, suggesting that these genes play a role in the occurrence and development of ovarian cancer. Judgment and treatment of patients with a certain degree of guiding significance. The complex interaction between genes, synergy needs further study.